Medtech startup Axio Biosolutions reports successful results from clinical trial of Axiostat Dental Haemostatic Dressing in Patients on Oral Antiplatelet Drugs
Bangalore: Nov 08 2017:
Axio Biosolutions, developer of novel 100% chitosan haemostat reported that its Axiostat Dental Haemostatic Dressing was found to be more than 10 times faster and efficient than standard gauze in arresting bleeding and facilitating healing of extraction wounds in patients on oral antiplatelet drugs in a recent clinical trial. Results were published recently in Journal of Contemporary Dental Practice 2017;18(9):802-806
This clinical trial was designed to assess the efficacy of Axiostat Dental Haemostatic Dressing in extraction wounds. 40 patients on oral antiplatelet drugs were included and 80 extractions were done applying split mouth study design, without altering patient’s drug regime. Study group achieved hemostasis in a mean of 1 minute 13 seconds, compared with control which took a mean of 14 minutes 1 second, which was statistically significant.
Average pain score in study group (1.93) was also considerably lower than in the control group (3.63) indicating a better comfort for patients treated with Axiostat Dental Haemostatic Dressing. There was also no evidence of postoperative trismus due to bleeding at local anesthetic injection sites nor was there any incidence of any untoward event, in any of the patients.
The results of this study could validate the use of Axiostat Dental Haemostatic Dressing in post extraction for preventing post extraction bleeding in patients on oral antiplatelet drugs as well as patients with increased bleeding tendency.
Axio Biosolutions, Founder & CEO Leo Mavely stated
“This is an important milestone for Axiostat Haemostatic range of products as it has demonstrated the efficacy in controlling bleeding even in presence of oral anti-platelet drugs. These results are consistent with device performance in various indications so far.”
About Axio Biosolutions:
Axio is a ISO 13485 medical device company with focus on advanced woundcare. Funded by Accel Partners, IDG Ventures, Axio uses innovative biopolymer based medical technology to create novel woundcare products. Its flagship product is Axiostat – a 100% chitosan haemostatic dressing that controls severe haemorrhage within minutes through its active adhesion to the trauma wound. The award winning CE approved product is being used in frontline battlefield by many defence forces across the globe. Axiostat is also used in cardio-vascular procedures to control bleeding during catheterization. Visit AxioBio for more information. Reach at LinkedIn or Twitter
